RaeSedo, Inc. has been selected to present its groundbreaking approach to asthma treatment at the prestigious 2024 ATS Respiratory Innovation Summit. This recognition underscores RaeSedo’s commitment to revolutionizing asthma care through innovative science and cutting-edge therapeutics.
As one of 25 companies chosen for this highly competitive event, RaeSedo is proud to showcase its novel therapeutic approach to asthma. The summit, held in May 2024, brings together industry leaders, innovators, and investors to discuss the latest advancements in respiratory health. Chief Medical Officer Dr. Monica Kraft presented on behalf of RaeSedo, highlighting its progress in addressing critical unmet needs in asthma treatment.
RaeSedo’s therapy leverages surfactant protein-A (SP-A), a natural protein found in the lungs, to reduce inflammation and improve lung function. The company’s lead candidate, C940, is designed for delivery through a simple, cost-effective inhaler, offering asthma patients a groundbreaking solution to manage their condition more effectively.
RaeSedo has developed SP-A-derived peptidomimetics that mimic the biological effects of SP-A while improving stability for therapeutic use. These innovations have demonstrated significant pre-clinical results, including reductions in airway inflammation, mucus production, and airway hyperresponsiveness. Partnerships with Lovelace Biomedical and Genscript have advanced development milestones, including aerosol formulation and upcoming toxicology studies.
Looking ahead, RaeSedo plans to file an Investigational New Drug application with the FDA in early 2025. With a global asthma therapeutics market projected to reach $37.8 billion by 2032, RaeSedo is well-positioned to address this growing demand. The company is actively seeking investment and development partners to bring its innovative therapies to market.
“By leveraging the body’s own biological processes, we aim to provide people with asthma with the first therapy that can reduce both inflammation and mucus, improving lung function.”
— Monica Kraft, MD Chief Medical Officer, RaeSedo, Inc.